Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02295501 · ClinicalTrials.gov registry record · Phase 1
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
A Phase 1 study, sponsored by Cerus Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02295501 is a Phase 1 study that was terminated before completion, run by Cerus Corporation. The registered enrollment target is 6 participants.
The verdict
NCT02295501, a Phase 1 study, was terminated before completion, sponsored by Cerus Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV. The risk of exposure to plasma from donors who may be infected with other transfusion-transmitted pathogens, not detectable by current licensed donor testing procedures, will be mitigated by using pathogen inactivation to minimize the risk of the TTI from these donors, who would otherwise be deferred and ineligible for blood donation.
Interventions
- BIOLOGICAL INTERCEPT Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12 |
| Est. Completion | 2020-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02295501
The ClinicalTrials.gov registry entry for NCT02295501 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INTERCEPT Plasma is the first listed.
NCT02295501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02295501 about?
NCT02295501 is a clinical study titled "A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease". The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV. The risk of exposure to plasma from donors who may be infected with other transfusion-transmitted pathogens, not detectable by current licen...
What is the current status of trial NCT02295501?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-12. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02295501?
The interventions under investigation include: INTERCEPT Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT02295501?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.